Goldman Sachs began coverage of United Therapeutics with a Sell rating, according to Investing.com. The same day, the bank also initiated MeiraGTx with a Neutral rating, giving investors two fresh reference points on gene-therapy and rare-disease names.
A Sell initiation from a major bank on an already-established biotech is unusual and tends to draw more attention than a routine buy call, because it implies the stock's current valuation or growth outlook does not match the price. The neutral stance on MeiraGTx suggests Goldman sees less conviction either way on that smaller, earlier-stage name.
The wire item does not include Goldman's price target or the specific reasoning behind the Sell call, so the thesis — whether it centers on pricing risk, competition, or valuation — remains unclear from what's been reported.